Hosted on MSN
FDA to weigh easing restrictions on seven peptides
The US Food and Drug Administration will review whether seven currently restricted peptides can be compounded by pharmacies, ...
As demand for GLP-1 therapies rises, like weight-loss drug Wegovy and diabetes treatment Ozempic, so do the legal and regulatory complexities facing compounders, prescribers and other stakeholders. In ...
Since 2022, four GLP-1 drugs, including those indicated for weight loss, have been on FDA’s drug shortage list due to extraordinarily high patient demand. The shortage has, in turn, resulted in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results